Study identification

EU PAS number

EUPAS1000000827

Study ID

1000000827

Official title and acronym

DARWIN EU® - Treatment characterisation and post-diagnosis outcomes in Alzheimer’s disease

DARWIN EU® study

Yes

Study countries

Croatia
Denmark
Germany
Netherlands

Study description

Alzheimer’s disease (AD) is the most common cause of dementia, characterised by progressive cognitive
decline and increasing loss of independence. Its burden is rising globally due to population ageing, with
substantial implications for healthcare systems and society. Recent therapeutic advances, such as the
approval of anti-amyloid monoclonal antibodies, are reshaping AD management, but also highlight the
need for updated real-world evidence on the epidemiology and characteristics of affected populations.

Study status

Planned
Research institutions and networks

Institutions

Networks

Contact details

Melissa Leung

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
EMA
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable